Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

AlloVir Says It Will Discontinue Its Three Phase 3 Posoleucel Studies Following Separate, Pre-planned DSMB Futility Analyses Concluding Studies Were Unlikely To Meet Primary Endpoints

Author: Benzinga Newsdesk | December 22, 2023 08:09am

As of September 30, 2023, AlloVir had cash, cash equivalents and short-term investments of $213.3 million.

Posted In: ALVR